Maxineb 2.5 mg (Tablet)

Unit Price: ৳ 7.00 (3 x 10: ৳ 210.00)
Strip Price: ৳ 70.00

Medicine Details

Category Details
Generic Nebivolol hydrochloride
Company Aristopharma ltd
Also available as
Maxineb 5 mg tablet

Title

  • Maxineb

Categories

  • Hypertension Medication
  • Cardiovascular Medication
  • Beta-blockers

Description

  • Indicated in Hypertension
  • Treatment of essential hypertension
  • Treatment of chronic heart failure (CHF)
  • Treatment of stable mild and moderate chronic heart failure
  • Pharmacology involves inhibition of β adrenergic receptors
  • Mode of Action includes decreased heart rate, myocardia contractility
  • Decrease in sympathetic outflow to the periphery
  • Suppression of renin activity
  • Vasodilation and decreased peripheral vascular resistance
  • Metabolized by glucuronidation and hydroxylation
  • Effective half-life of about 12 hours
  • Peak plasma concentrations occur approximately 1.5 to 4 hours post-dosing
  • Absorption is similar to an oral solution
  • Plasma protein binding is approximately 98%
  • Primarily metabolized via direct glucuronidation
  • 38% of the dose was recovered in urine and 44% in feces
  • No significant changes in the pharmacokinetics when administered with digoxin
  • No significant changes in the pharmacokinetics when administered with warfarin
  • Starting dose should be reduced in patients with moderate hepatic impairment
  • Contraindicated in patients with severe bradycardia
  • Contraindicated in patients with heart block greater than first degree
  • Contraindicated in patients with severe hepatic impairment
  • Contraindicated in patients who are hypersensitive to any component of this product
  • Common side effects include headache, nausea, bradycardia
  • The recommended starting dose is 5 mg once daily
  • Dose can be increased at 2-week intervals up to 40 mg
  • Should be used with care when myocardial depressants or inhibitors of AV conduction are used concurrently
  • Should not be combined with other β-blockers
  • Use caution when co-administered with CYP2D6 inhibitors
  • Patients with coronary artery disease should be advised against abrupt discontinuation of therapy
  • Patients with congestive heart failure should be administered cautiously
  • Should not be used in patients with bronchospastic diseases
  • Patients should be closely monitored during anesthesia and major surgery
  • β-blockers may mask some of the manifestations of hypoglycemia
  • β-blockers may mask clinical signs of hyperthyroidism
  • β-blockers can precipitate or aggravate symptoms of arterial insufficiency
  • Caution should be used in patients concomitantly treated with calcium channel blockers
  • Should be used with caution in patients with severe renal impairment
  • Should be used with caution in patients with moderate hepatic impairment
  • Keep below 30°C temperature, away from light & moisture
  • Keep out of the reach of children

Related Brands